期刊文献+
共找到108篇文章
< 1 2 6 >
每页显示 20 50 100
氨基甾体类肌松药拮抗剂sugammadex的研究进展 被引量:1
1
作者 王宏 戴体俊 《中国药理学通报》 CAS CSCD 北大核心 2012年第4期466-469,共4页
Sugammadex是一种修饰的γ-环糊精,能与氨基甾体类肌松药形成紧密复合体而逆转它们的肌松作用,与新斯的明相比具有明显的优势,并能安全、有效地用于婴幼儿、孕妇、心、肾功能受损和重症肌无力患者。Sugammadex的临床应用将会为临床麻醉... Sugammadex是一种修饰的γ-环糊精,能与氨基甾体类肌松药形成紧密复合体而逆转它们的肌松作用,与新斯的明相比具有明显的优势,并能安全、有效地用于婴幼儿、孕妇、心、肾功能受损和重症肌无力患者。Sugammadex的临床应用将会为临床麻醉工作带来新的变革。 展开更多
关键词 氨基甾体类肌松药 罗库溴铵 肌松作用 拮抗剂 sugammadex 逆转
下载PDF
Sugammadex(Org25969)研究进展
2
作者 徐四七 胡胜红 李元海 《安徽医药》 CAS 2008年第6期481-482,共2页
关键词 sugammadex 库溴铵 神经肌肉阻滞
下载PDF
特异性肌松拮抗药Sugammadex研究进展
3
作者 高巨 徐少群 《麻醉与监护论坛》 2007年第5期298-301,共4页
Sugammadex是一种新型的特异性甾体类非去极化肌松药掊抗药,它并不作用于胆碱脂酶,主要直接和氨基甾体类肌松药结合,通过其独特的化学螯合作用,可快速,安全、有效,并呈剂量相关性逆转由罗库溴铵等甾体类肌松药所导致的神经肌肉阻... Sugammadex是一种新型的特异性甾体类非去极化肌松药掊抗药,它并不作用于胆碱脂酶,主要直接和氨基甾体类肌松药结合,通过其独特的化学螯合作用,可快速,安全、有效,并呈剂量相关性逆转由罗库溴铵等甾体类肌松药所导致的神经肌肉阻滞作用,开创了一种全新的肌松拮抗机制。 展开更多
关键词 特异性肌松拮抗药 sugammadex Org25969
下载PDF
肌松药拮抗药Sugammadex的临床应用进展 被引量:3
4
作者 王耘 曹永兵 +1 位作者 姜远英 颜天华 《药学实践杂志》 CAS 2012年第6期405-407,453,共4页
2008年Sugammadex在欧洲获准上市,用于拮抗由罗库溴铵和维库溴铵介导的神经肌肉功能阻滞,显示出较好的有效性和安全性。本文主要关注Sugammadex在常规临床实践中和紧急情况下,对于肌松药物使用所产生的影响,以及Sug-ammadex在特殊人群... 2008年Sugammadex在欧洲获准上市,用于拮抗由罗库溴铵和维库溴铵介导的神经肌肉功能阻滞,显示出较好的有效性和安全性。本文主要关注Sugammadex在常规临床实践中和紧急情况下,对于肌松药物使用所产生的影响,以及Sug-ammadex在特殊人群患者中的作用效果。 展开更多
关键词 肌松拮抗 sugammadex 罗库溴铵 琥珀胆碱 新斯的明
下载PDF
Sugammadex is associated with better respiratory recovery than neostigmine following reversal of anaesthesia-associated neuromuscular blockade in the morbidly obese patients following elective laparoscopic surgery 被引量:1
5
作者 M.Johnson O.A.Khan +3 位作者 E.R.McGlone A.A.Roman J.S.Qureshi A.Kayal 《Laparoscopic, Endoscopic and Robotic Surgery》 2018年第2期33-36,共4页
Complete and reliable neuromuscular reversal is important to successful anaesthetic recovery in the morbidly obese patient undergoing laparoscopic surgery.Our goal was to determine whether sugammadex,a selective rever... Complete and reliable neuromuscular reversal is important to successful anaesthetic recovery in the morbidly obese patient undergoing laparoscopic surgery.Our goal was to determine whether sugammadex,a selective reversal agent is associated with better respiratory recovery than neostigmine following the reversal of anaesthesia-associated neuromuscular blockade by rocuronium in the morbidly obese.Peak Expiratory Flow Rate a surrogate marker for respiratory function,was the primary outcome measured and secondary outcome measures included post-operative nausea and vomiting,pain and head lifting.We found that patients reversed with sugammadex had a significantly higher post-operative PEFR as compared to those reversed with neostigmine and glycopyrrolate group. 展开更多
关键词 sugammadex Laparoscopic surgery Neuromuscular blockade Morbidly obese
下载PDF
Unexpected delayed reversal of rocuronium-induced neuromuscular blockade by sugammadex:A case report and review of literature
6
作者 Hao-Chen Wang Cheng-Wei Lu +1 位作者 Tzu-Yu Lin Ya-Ying Chang 《World Journal of Clinical Cases》 SCIE 2022年第35期13138-13145,共8页
BACKGROUND Rocuronium,a nondepolarizing muscle relaxant,is usually administered during general anesthesia to facilitate endotracheal intubation and keep patients immobile during the surgery.Sugammadex,the selective re... BACKGROUND Rocuronium,a nondepolarizing muscle relaxant,is usually administered during general anesthesia to facilitate endotracheal intubation and keep patients immobile during the surgery.Sugammadex,the selective reversal agent of rocuronium,fully reverses the neuromuscular blockade(NMB)at the end of surgery.Most reports show that sugammadex rapidly achieves a ratio of train-offour(TOF),a quantitative method of neuromuscular monitoring,of 0.9 which ensures adequate recovery for safe extubation.However,very rare patients with neuromuscular diseases may respond poorly to sugammadex.CASE SUMMARY A 69-year-old female presented with abdominal fullness and nausea,and was diagnosed with gastroparesis.She underwent gastric peroral endoscopic myotomy under general anesthesia with rocuronium(0.7 mg/kg).At the end of surgery,sugammadex 3.6 mg/kg was administered when TOF showed 2 counts.Afterward,the TOF ratio recovered to 0.65 in 30 min.She was awake but could not fully open her eyelids.The tidal volume during spontaneous breathing was low.After additional doses of sugammadex(up to 7.3 mg/kg)in the following 3 h,the TOF ratio was 0.9,and the endotracheal tube was smoothly removed.After excluding possible mechanisms underlying the prolonged recovery course,we speculated our patient may have had an undiagnosed neuromuscular disease,hinted by her involuntary movement of the tongue and mouth.Furthermore,her poor renal function and history of delayed recovery from general anesthesia may be related to the long duration of rocuronium.CONCLUSION In our case,both prolonged rocuronium-induced NMB and poor response to sugammadex were noted.To optimize the dose of rocuronium,perioperative TOF combined with other neuromuscular monitoring is suggested. 展开更多
关键词 sugammadex TRAIN-OF-FOUR ROCURONIUM Neuromuscular blockade General anesthesia Case report
下载PDF
Successful Use of Sugammadex in a Myasthenic Patient Case Report
7
作者 Silvia Kangassu Rios Daiana Gomes +2 位作者 Marcos Lopes De Miranda Carlos Frederico La Cava Carlos Darcy Bersot 《Open Journal of Anesthesiology》 2013年第1期48-50,共3页
The Myasthenia gravis (MG) is an autoimmune disease that affects neuromuscular transmission and leads to a large variation of sensibility on depolarizing and nondepolarizing neuromuscular blocking drugs. Sugammadex is... The Myasthenia gravis (MG) is an autoimmune disease that affects neuromuscular transmission and leads to a large variation of sensibility on depolarizing and nondepolarizing neuromuscular blocking drugs. Sugammadex is a new drug with the capability to successfully revert the nondepolarizing neuromuscular blocking. This case report will show a patient with MG that was scheduled for thymectomy, with the objective to use sugammadex to reverse a rocuronium induced deep level of neuromuscular block and observing the safe use of sugammadex without complications. 展开更多
关键词 sugammadex MYASTHENIA GRAVIS ROCURONIUM NEUROMUSCULAR Monitoring ANESTHESIA
下载PDF
Effective Use of Sugammadex for Incomplete Pyridostigmine Reversal of Muscle Relaxation by Rocuronium: A Case Report
8
作者 Hee Jong Lee Kyo Sang Kim +2 位作者 Ji Seon Jeong Sung Hwan Choi Kyu Nam Kim 《Open Journal of Anesthesiology》 2013年第9期393-395,共3页
Anticholinesterase does not allow adequate reversal of the deep neuromuscular blockade (NMB) achieved using high doses of relaxants. A 71-year-old female patient (weight 70 kg, height 169 cm) was scheduled for a trans... Anticholinesterase does not allow adequate reversal of the deep neuromuscular blockade (NMB) achieved using high doses of relaxants. A 71-year-old female patient (weight 70 kg, height 169 cm) was scheduled for a transurethral resection of a bladder tumor under general anesthesia. We administered rocuronium 30 mg (0.43 mg/kg) for tracheal intubation due to an estimated short surgical time. During the operation, an additional rocuronium 10 mg was injected. The surgical procedure ended abruptly 10 minutes after receiving the last dose of rocuronium. At the end of surgery, the patient received pyridostigmine as a reversal. However, residual NMB persisted, and neuromuscular monitoring did not show the expected degree of recovery. Sugammadex 2 mg/kg was used, and the patient experienced complete reversal from NMB in just 2 min. 展开更多
关键词 PYRIDOSTIGMINE RESIDUAL Block ROCURONIUM sugammadex
下载PDF
Sugammadex: Role in current anaesthetic practice and its safety benefits for patients
9
作者 Michael V Copp Thomas F Barrett 《World Journal of Anesthesiology》 2015年第3期66-72,共7页
Sugammadex has revolutionized anaesthetic management of reversal of neuromuscular block(NMB) by way of its unique mechanism of action encapsulating the amino steroid neuromuscular blocking drugs rocuroniumand vecuroni... Sugammadex has revolutionized anaesthetic management of reversal of neuromuscular block(NMB) by way of its unique mechanism of action encapsulating the amino steroid neuromuscular blocking drugs rocuroniumand vecuronium. The cholinesterase inhibitors have significant pharmacological and clinical limitations whereas sugammadex allows predictable, safe and rapid reversal from any depth of blockade. The financial cost of sugammadex is significant. Many hospitals in the United Kingdom use clinical guidelines to direct best use of sugammadex in their institutions. Auditing the use of sugammadex provides useful information on which patients are benefiting from sugammadex. The clinical benefits of sugammadex are well understood. No patient should now be subjected to the danger of post-operative residual curarization. Versatility in the ability to reverse NMB has brought opportunities to the anaesthetist in the management of rapid sequence induction using high dose rocuronium with the knowledge that safe reversal of NMB is now possible in the unlikely event of a "can't intubate can't ventilate" situation. Do we still need suxamethonium to be available? The nature of surgery continues to evolve with ever-increasing enthusiasm for minimally invasive laparoscopic techniques. There is evidence to support using a deeper level of NMB to improve the working space and operating conditions in laparoscopic surgery. It is now possible to maintain a deep level of NMB right up until the end of surgery with no concerns about the ability to effect safe reversal of NMB. Vigilance about the possibility of allergic sensitivity to sugammadex needs to be maintained. The increased usage of rocuronium has the potential for rocuroniuminduced anaphylaxis. Conversely, there is a potential role for sugammadex in the treatment of rocuronium anaphylaxis. Clinicians who have used sugammadex are struck with the quality of recovery seen in their patients. It is important that the economic implications of the use of sugammadex are fully understood. This article considers the current role of sugammadex in clinical practice outside of routine reversal of NMB and discusses how the addition of sugammadex to the anaesthetic armamentarium brings safety benefits for patients. 展开更多
关键词 sugammadex NEUROMUSCULAR BLOCK Clinical BENEFITS PATIENT safety Cost BENEFIT
下载PDF
The Safe Use of Sugammadex “Rescue” after Neostigmine: 2 Case Reports
10
作者 Joseph F. Answine 《Open Journal of Anesthesiology》 2016年第9期125-127,共4页
With the introduction of the rocuronium and vecuronium binding agent sugammadex into clinical practice in the United States, its use for reversal of neuromuscular blockade will likely start in some institutions as a ... With the introduction of the rocuronium and vecuronium binding agent sugammadex into clinical practice in the United States, its use for reversal of neuromuscular blockade will likely start in some institutions as a “rescue” after failed reversal with neostigmine. However, sugammadex after neostigmine has not been extensively studied. Therefore, there is a question as to its effectiveness when used in this way especially in the airway compromised patients that the anesthesia provider will commonly face in this situation. Furthermore, there is a possibility of hemodynamic compromise. These two case reports demonstrate the safe and effective use of sugammadex after failed reversal with neostigmine. 展开更多
关键词 sugammadex NEOSTIGMINE Reversal Airway Hemodynamics ROCURONIUM VECURONIUM Neuromuscular Blockade Nicotinic Weakness BRADYCARDIA TRAIN-OF-FOUR
下载PDF
Sugammadex in the Management of Sinus Tachycardia after Rocuronium Administration: A Case Report
11
作者 Eduardo Fernandes Orioli Guimaraes Muriel Mofreita Saldanha +3 位作者 Tiago Coelho Fortes Marcelo Grisolia Marcos Lopes de Miranda Carlos Darcy Alves Bersot 《Open Journal of Anesthesiology》 2014年第9期203-206,共4页
In rare cases, rocuronium has been associated with dose-related tachycardia, probably by a cardiac muscarinic M2 receptor blockade mechanism. We report the case of a 30-year-old female who underwent excision of a bran... In rare cases, rocuronium has been associated with dose-related tachycardia, probably by a cardiac muscarinic M2 receptor blockade mechanism. We report the case of a 30-year-old female who underwent excision of a branchial cyst under general anesthesia. This patient presented an episode of sinus tachycardia (130 bpm) shortly after anesthesia induction with propofol, sufentanyl, and rocuronium. Tachycardia could not be explained by any cause other than the use of rocuronium, which was reverted with sugammadex. Two minutes after sugammadex administration, heart rate normalized, corroborating our hypothesis that rocuronium induced the sinus tachycardia observed in our patient. The patient recovered well from the anesthetic-surgical procedure and showed no further cardiovascular, ventilatory, or neurological changes, being transferred to the post-anesthesia care unit, and finally discharged to the ward. 展开更多
关键词 ROCURONIUM sugammadex ANESTHESIA Sinus Tachycardia
下载PDF
Efficacy of different doses of sugammadex after continuous infusion of rocuronium
12
作者 Diego Soto Mesa Mounir Fayad Fayad +5 位作者 Laura Pérez Arviza Verónica Del Valle Ruiz Fernando Cosío Carreño Luis Arguelles Tamargo Manuel Amorín Díaz Sergio Fernández-Pello Montes 《World Journal of Clinical Cases》 2015年第4期360-367,共8页
AIM: To evaluate the effects of two different doses of sugammadex after maintenance anesthesia with sevofluorane and remifentanil and deep rocuroniuminduced neuromuscular blockade(NMB).METHODS: Patients between 20 and... AIM: To evaluate the effects of two different doses of sugammadex after maintenance anesthesia with sevofluorane and remifentanil and deep rocuroniuminduced neuromuscular blockade(NMB).METHODS: Patients between 20 and 65 years of age, with American Society of Anesthesiologists physical status classification Ⅰ-Ⅱ, undergoing gynecological surgery were included in a prospective, comparative and randomized study. NMB was induced with an injection of 0.6 mg/kg of rocuronium followed by continuous infusion of 0.3-0.6 mg/kg per hour to maintain a deep block. Anesthesia was maintained with sevofluorane and remifentanil. Finally, when surgery was finished, a bolus of 2 mg/kg(group A) or 4 mg/kg(group B) of sugammadex was applied when the NMB first response in the train-of-four was reached. The primary clinical endpoint was time to recovery to a train-of-four ratio of 0.9. Other variables recorded were the time until recovery of train-of-four ratio of 0.7, 0.8, hemodynamic variables(arterial blood pressure and heart rate at baseline, starting sugammadex, and minutes 2, 5 and 10) and adverse events were presented after one hour in the post-anesthesia care unit.RESULTS: Thirty-two patients were included in the study: 16 patients in group A and 16 patients in group B. Only 14 patients each group were recorded because arterial pressure values were lost in two patients from each group in minute 10. The two groups were comparable. Median recovery time from starting of sugammadex administration to a train-of-four ratio of 0.9 in group A and B was 129 and 110 s, respectively.The estimated difference in recovery time between groups was 24 s(95%CI: 0 to 45 s, Hodges-Lehmann estimator), entirely within the predefined equivalence interval. Times to recovery to train-of-four ratios of 0.8(group A: 101 s; group B: 82.5 s) and 0.7(group A: 90 s; group B: 65 s) from start of sugammadex administration were not equivalent between groups. There was not a significant variation in the arterial pressure and heart rate values between the two groups and none of the patients showed any clinical evidence of residual or recurrent NMB. CONCLUSION: A dose of 2 mg/kg of sugammadex after continuous rocuronium infusion is enough to reverse the NMB when first response in the Train-OfFour is reached. 展开更多
关键词 ROCURONIUM sugammadex Neuromuscular block antagonism Monitoring neuromuscular function Neuromuscular block rocuronium
下载PDF
Superiority of sugammadex in preventing postoperative pulmonary complications
13
作者 Haibei Liu Rong Luo +3 位作者 Shuangjiao Cao Bixing Zheng Ling Ye Wensheng Zhang 《Chinese Medical Journal》 SCIE CAS CSCD 2023年第13期1551-1559,共9页
Background:Postoperative pulmonary complications often lead to increased mortality and financial burden.Residual paralysis plays a critical role in postoperative pulmonary complications.This meta-analysis was performe... Background:Postoperative pulmonary complications often lead to increased mortality and financial burden.Residual paralysis plays a critical role in postoperative pulmonary complications.This meta-analysis was performed to determine whether sugammadex overmatches neostigmine in reducing postoperative pulmonary complications.Methods:PubMed,Embase,Web of Science,Medline through Ovid,Cochrane Library,Wanfang,China National Knowledge Infrastructure,and Chinese BioMedical Literature Databases were searched from their inception to 24 June,2021.Random effects models were used for all analyses.Cochrane risk of bias tool was used to assess the quality of RCTs,while Newcastle Ottawa Quality Assessment Scale was used to assess for the quality of cohort studies.Results:Seventeen studies were included in the meta-analysis.Pooled data from cohort studies showed reversing neuromuscular blocking with sugammadex had less risk of compound postoperative pulmonary complications(relative risk[RR]:0.73;95%confidence interval[CI]:0.60-0.89;P=0.002;I^(2)=81%),pneumonia(RR:0.64;95%CI:0.48-0.86;I^(2)=42%)and respiratory failure(RR:0.48;95%CI:0.41-0.56;I^(2)=0%).However,pooled data from RCTs did not show any difference between the two groups in pneumonia(RR:0.58;95%CI:0.24-1.40;I^(2)=0%)and no respiratory failure was reported in the included RCTs.The difference was not found between sugammadex and neostigmine about atelectasis in pooled data from either RCTs(RR:0.85;95%CI:0.69-1.05;I^(2)=0%)or cohort studies(RR:1.01;95%CI:0.87-1.18;I^(2)=0%).Conclusion:The evidence of superiority of sugammadex was limited by the confounding factors in cohort studies and small scale of RCTs.Whether sugammadex precedes neostigmine in preventing pulmonary complications after surgery is still unknown.Well-designed RCTs with large scale are needed.Registration:PROSPERO(https://www.crd.york.ac.uk/PROSPERO/);CRD 42020191575. 展开更多
关键词 sugammadex NEOSTIGMINE Pulmonary complications PNEUMONIA PARALYSIS
原文传递
新型肌松药拮抗剂sugammadex ( Org 25969)临床研究进展 被引量:3
14
作者 周桥灵 杨承祥 《国际麻醉学与复苏杂志》 CAS 2009年第2期185-188,共4页
此文综述sugammade近年来的临床研究概况。文章认为sugammadex可安全有效拮抗罗库溴铵的肌松效应,其效能呈剂量依赖性。同时也可安全有效拮抗未成年人、老年人或心脏病患者、肺病患者和肾衰患者罗库溴铵的肌松效应,副作用少。与传统... 此文综述sugammade近年来的临床研究概况。文章认为sugammadex可安全有效拮抗罗库溴铵的肌松效应,其效能呈剂量依赖性。同时也可安全有效拮抗未成年人、老年人或心脏病患者、肺病患者和肾衰患者罗库溴铵的肌松效应,副作用少。与传统肌松拮抗药比较,sugammadex具有显著优势,有广泛应用前景。 展开更多
关键词 肌松药拮抗剂 sugammadex 罗库溴铵
原文传递
新型选择性肌松药拮抗药——sugammadex临床研究进展 被引量:1
15
作者 童珊珊 闵苏 《中国新药与临床杂志》 CAS CSCD 北大核心 2010年第5期382-386,共5页
sugammadex是一种新型肌松药拮抗药,可以选择性包裹甾类肌松药,有效、快速拮抗不同深度神经肌肉阻滞作用,相对于新斯的明有明显优势。并能安全有效地应用于肾功能受损、心脏病及肺病患者,不良反应少。sugammdex的使用可能是麻醉用药的... sugammadex是一种新型肌松药拮抗药,可以选择性包裹甾类肌松药,有效、快速拮抗不同深度神经肌肉阻滞作用,相对于新斯的明有明显优势。并能安全有效地应用于肾功能受损、心脏病及肺病患者,不良反应少。sugammdex的使用可能是麻醉用药的变革之一。 展开更多
关键词 神经肌肉药 罗库溴铵 维库溴铵 肌松药拮抗药 sugammadex
原文传递
Sugammadex和新斯的明对氨基甾体类肌松药肌松拮抗效果及安全性的系统评价 被引量:5
16
作者 蒋卫光 崔常雷 韩树海 《国际麻醉学与复苏杂志》 CAS 2014年第2期138-144,共7页
目的系统评价Sugammadex和新斯的明对氨基甾体类肌松药诱导肌肉松弛的拮抗效果和副作用。方法计算机检索PubMed、EBSCO、Springer、Ovid、Embase、CochraneLibrary和CNKI、万方数据库,检索起止时间为从建库至2013年6月。收集Sugammade... 目的系统评价Sugammadex和新斯的明对氨基甾体类肌松药诱导肌肉松弛的拮抗效果和副作用。方法计算机检索PubMed、EBSCO、Springer、Ovid、Embase、CochraneLibrary和CNKI、万方数据库,检索起止时间为从建库至2013年6月。收集Sugammadex和新斯的明用于拮抗肌肉松弛的随机对照试验(randomizedcontrolledtrial,RCT),由2位研究者对纳入研究进行资料提取和质量评价后,采用RevMan5.2软件进行Meta分析。结果纳入6个RCT,包括533例患者。Meta分析:无论是中度还是深度神经肌肉阻滞,Sugammadex组四个成串刺激(train-of-four,TOF)值恢复到70%、80%和90%的平均时间明显快于新斯的明组。深度TOF值恢复到70%、80%、90%的平均时间分别为[WMD=-31.37,95%CI(-39.08,-23.66),P〈0.00001]、lWMD=-39.27,95%CI(-48.48,-30.05),P〈0.00001]和[WMD=-46.36,95%CI(-56.03,-36.69),19〈0.00001],中度TOF值恢复到70%、80%、90%的平均时间分别为[WMD=-5.13,95%CI(-7。38,-2。89),P〈O.00001]、[WMD-11.65,95%CI(-13.48,-9.82),P〈0.00001]和[WMD=-18.43,95%CI(-23.80,-13.05),P〈0.00001]。同时Sugammadex组患者发生药物相关副作用的概率小于新斯的明组,其差异有统计学意义[OR=0.54,95%CI(0.35,0.85),P=-O.007]。结论在中度和深度神经肌肉阻滞情况下,和新斯的明组比较,Sugammadex组对氨基甾体类肌松药诱导肌肉松弛的拮抗效果更强、安全性更高。 展开更多
关键词 sugammadex 新斯的明 神经肌肉阻滞 系统评价 META分析
原文传递
舒更葡糖钠对胸腔镜肺癌根治术后患者肌松恢复及凝血功能的影响
17
作者 李箫 张子洲 王伟 《新疆医科大学学报》 CAS 2024年第2期259-263,共5页
目的探讨舒更葡糖钠注射液对胸腔镜肺癌根治术后患者肌松恢复及凝血功能的影响。方法选取2020年2月至2022年1月在江苏大学附属镇江三院、常州市第七人民医院于全麻下行胸腔镜肺癌根治术的86例患者为研究对象。应用随机数字表法将患者分... 目的探讨舒更葡糖钠注射液对胸腔镜肺癌根治术后患者肌松恢复及凝血功能的影响。方法选取2020年2月至2022年1月在江苏大学附属镇江三院、常州市第七人民医院于全麻下行胸腔镜肺癌根治术的86例患者为研究对象。应用随机数字表法将患者分成A、B两组,每组各43例。两组麻醉诱导和术中全麻维持方案相同,使用肌松监测仪(TOF)监测肌松。手术结束后,TOF计数≥2时,A组静脉推注新斯的明(2 mg/kg)、阿托品(0.5 mg/kg)逆转肌松药,B组静脉推注舒更葡糖钠(2 mg/kg)。记录推注肌松拮抗药后5、15、30 min时肌松残余率。观察注射罗库溴铵后5 min(T0)、推注肌松拮抗药后5 min(T1)、15 min(T2)、30 min(T3)时血浆凝血酶时间(TT)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、纤维蛋白原(FIB)水平。同时记录气管导管拔除时间及患者发生恶心、呕吐等情况。结果A组给予肌松拮抗药5、15 min后肌松残余率明显高于B组(100.00%vs 13.95%,65.12%vs 0.00%)(χ^(2)=64.939、41.517,P<0.01)。两组患者在相同时间点TT、APTT、PT、FIB指标差异均无统计学意义(P均>0.05)。B组气管导管拔管时间[(3.8±1.1)min]短于A组[(13.9±4.3)min],差异有统计学意义(t=14.922,P<0.001);B组呼吸抑制发生率低于A组(0.00%vs 11.63%)(χ^(2)=5.309,P=0.021)。结论舒更葡糖钠注射液用于胸腔镜肺癌根治术患者,可快速拮抗罗库溴铵的肌松作用,降低肌松残余发生率,缩短气管导管拔管时间,利于患者术后康复。 展开更多
关键词 胸腔镜肺癌根治术 舒更葡糖钠 残余肌松 凝血功能
下载PDF
舒更葡糖钠对胸腔镜肺切除术后恢复的影响
18
作者 仇蕾 夏肇敏 +5 位作者 黄茜 李彭欣 王玉东 宋田皓 辜晓岚 顾连兵 《临床麻醉学杂志》 CAS CSCD 北大核心 2024年第6期581-586,共6页
目的探讨舒更葡糖钠对胸腔镜肺切除术后肺部并发症(PPCs)及术后恢复的影响。方法选择2021年11月至2023年7月接受择期胸腔镜肺段切除术或肺叶切除术的患者263例,男112例,女151例,年龄18~64岁,BMI 18.5~28.0 kg/m^(2),ASAⅠ—Ⅲ级。将患... 目的探讨舒更葡糖钠对胸腔镜肺切除术后肺部并发症(PPCs)及术后恢复的影响。方法选择2021年11月至2023年7月接受择期胸腔镜肺段切除术或肺叶切除术的患者263例,男112例,女151例,年龄18~64岁,BMI 18.5~28.0 kg/m^(2),ASAⅠ—Ⅲ级。将患者随机分为三组:舒更葡糖钠组(S组,n=88)、新斯的明组(N组,n=87)和对照组(C组,n=88)。患者术后被送至PACU,当四个成串刺激(TOF)计数为2时,S组静脉注射舒更葡糖钠2 mg/kg,N组静脉注射新斯的明0.04 mg/kg+阿托品0.02 mg/kg,C组静脉注射等容量生理盐水。记录手术结束至出院前PPCs的发生情况,记录手术结束至拔管时间、给药至四个成串刺激比值(TOFr)恢复至0.9的时间、拔管时TOFr、PACU停留时间、拔管后低氧血症(SpO_(2)<90%)的情况并计算拔管时肌松残余(PRNB)发生率,记录首次下床活动时间、术后48 h内镇痛泵总按压次数、有效按压次数、补救镇痛例数、临床肺部感染评分(CPIS)、术后恶心呕吐(PONV)例数、胸管总引流量、胸管留置时间和术后住院时间。结果与C组比较,S组PPCs发生率、拔管时PRNB和拔管后低氧血症发生率明显降低,手术结束至拔管时间、给药至TOFr恢复至0.9的时间、PACU停留时间和术后首次下床活动时间明显缩短,拔管时TOFr明显升高,CPIS评分明显降低(P<0.05);N组手术结束至拔管时间、给药至TOFr恢复至0.9的时间、PACU停留时间明显缩短,拔管时TOFr明显升高,拔管时PRNB发生率明显降低(P<0.05)。与N组比较,S组拔管时PRNB发生率明显降低,手术结束至拔管时间、给药至TOFr恢复至0.9的时间、PACU停留时间和术后首次下床活动时间明显缩短,拔管时TOFr明显升高(P<0.05)。三组其余指标差异均无统计学意义。结论舒更葡糖钠在胸腔镜肺切除术后可快速拮抗残余肌松,降低PPCs和拔管时PRNB发生率,促进患者术后快速康复。 展开更多
关键词 舒更葡糖钠 胸腔镜肺切除术 术后肺部并发症 术后恢复
下载PDF
舒更葡糖钠对腹腔镜下胆囊切除术围拔管期血流动力学和相关并发症的影响
19
作者 纪亚男 陈凯 李晓芳 《中国医药》 2024年第4期558-561,共4页
目的 探讨舒更葡糖钠对腹腔镜下胆囊切除术围拔管期血流动力学和相关并发症的影响。方法 选取2019年6月至2022年6月于新疆医科大学第五附属医院行腹腔镜下胆囊切除术患者120例,依照随机数字表法分为对照组和观察组,各60例。对照组手术... 目的 探讨舒更葡糖钠对腹腔镜下胆囊切除术围拔管期血流动力学和相关并发症的影响。方法 选取2019年6月至2022年6月于新疆医科大学第五附属医院行腹腔镜下胆囊切除术患者120例,依照随机数字表法分为对照组和观察组,各60例。对照组手术结束后未给予肌松拮抗药物,观察组手术结束后给予舒更葡糖钠静脉滴注。比较2组围拔管期心率、收缩压及舒张压,术前和术后即刻的血清促肾上腺皮质激素(ACTH)、皮质醇水平,术后拔管时间、4个成串刺激计数(TOF)恢复时间、麻醉后监测治疗室(PACU)停留时间及低氧血症发生率、心律失常发生率。结果 对照组拔管后1、5、10 min的心率、收缩压及舒张压均高于拔管前(均P<0.05)。观察组拔管后1、5、10 min的心率、收缩压及舒张压与拔管前比较差异均无统计学意义(均P>0.05),且收缩压、舒张压均低于对照组(均P<0.05)。2组术后即刻血清ACTH、皮质醇水平均高于术前,但观察组均低于对照组(均P<0.05)。观察组术后拔管时间、TOF恢复时间及PACU停留时间均短于对照组[(2.2±1.0)min比(31.1±10.1)min、(55±8)min比(74±12)min、(35±9)min比(48±13)min](均P<0.001)。观察组术后低氧血症和心律失常发生率均低于对照组[8.3%(5/60)比33.3%(20/60)、1.7%(1/60)比13.3%(8/60)](均P<0.05)。结论 在腹腔镜下胆囊切除术后应用舒更葡糖钠能维持患者血流动力学,减轻机体应激反应,并降低拔管后并发症发生率。 展开更多
关键词 腹腔镜下胆囊切除术 围拔管期 舒更葡糖钠 血流动力学
下载PDF
顶空气相色谱法测定舒更葡糖钠原料药中7种有机溶剂的残留量 被引量:1
20
作者 李圆圆 万艳武 焦东洋 《安徽化工》 CAS 2024年第2期162-164,184,共4页
目的:建立测定舒更葡糖钠原料药中甲醇、乙醇、丙酮、丙烯腈、丙烯酸甲酯、苯和丙烯酸乙酯7种有机溶剂残留量的方法。方法:采用顶空气相色谱法,色谱柱为DB-624毛细管柱(30 m×0.32 mm,1.8μm),柱温采用程序升温,进样口温度200℃,检... 目的:建立测定舒更葡糖钠原料药中甲醇、乙醇、丙酮、丙烯腈、丙烯酸甲酯、苯和丙烯酸乙酯7种有机溶剂残留量的方法。方法:采用顶空气相色谱法,色谱柱为DB-624毛细管柱(30 m×0.32 mm,1.8μm),柱温采用程序升温,进样口温度200℃,检测器为氢火焰离子化检测器,温度250℃,载气为高纯氮气,载气流速3.0 mL/min,分流比10∶1,顶空平衡温度60℃,平衡时间30 min。结果:各有机溶剂分离度良好,7种有机溶剂在各自质量浓度范围内与相应色谱峰峰面积线性关系良好(r=0.9981~0.9999),平均回收率91.6%~104.3%。结论:该方法快捷、准确、灵敏度高,可用于舒更葡糖钠原料药中甲醇、乙醇、丙酮、丙烯腈、丙烯酸甲酯、苯和丙烯酸乙酯残留量的测定。 展开更多
关键词 舒更葡糖钠 顶空气相色谱法 残留溶剂 原料药
下载PDF
上一页 1 2 6 下一页 到第
使用帮助 返回顶部